Subscribe to Pro or Enterprise plans to unlock this feature.
Become a smarter investor today.
Become a smarter investor today.
This statistic highlights Viatris’ Revenue Breakdown by Region, split across France, India, and US regions.
Viatris became a public company in November 2020 and produces medicines that cure 9 out of the 10 diseases in the list of World Health Organisation’s leading causes of death. The headquarters of Viatris is in the United States, with its global centers in Pittsburgh, Pennsylvania, Shanghai, China, and Hyderabad, India.
Viatris’ Revenue Breakdown by Region
Viatris’ generates its revenue mainly from the sale of the medicines. Its revenue decreased from $6.17 billion in 2019, to $5.96 billion in 2020, marking a 3.4% fall in the total revenue on a year-on-year basis.
The company’s revenue comes mainly from three nations – France, India and the US. Further breakdown of revenue, from each of these locations, is provided in the table below:
|Revenue by Region||2019||2020||Contribution in 2020|
(All figures are in the billions, except percentages)
The share of the revenue from France stood at $1.07 billion in the year 2020 with a share of 18% in the total revenue and increased 2.88% from the year 2019 when the revenue from France was $1.04 billion.
The share of the revenue from India stood at $1.15 billion in the year 2020, a fall of 1.7% from the year 2019 when its revenue from India was $1.17 billion. The revenue from India had a 19% share in the total revenue of Viatris Inc. in 2020.
The US contributed 63% of the revenues of Viatris Inc in the year 2020. Revenue from the US in 2020 was $3.74 billion as compared to $3.96 billion in 2019, declining 5.5% on year on year basis.
About the Company
Viatris Inc. is a global healthcare company with a mission to empower people all over the world to live healthier at every stage of life. It aims to bring together some of the industry’s best talent and provide an unparalleled business platform in service to patients, regardless of their location or condition. The company believes that it is uniquely positioned to deliver increased access to affordable, quality medicines for patients all over the world. It was created by merging Mylan and Upjohn, a division of Pfizer. The combined company is believed to have industry-leading R&D, medical, regulatory, manufacturing, supply chain, and commercial expertise complemented by an unequivocal commitment to quality and a global geographic footprint that is capable of delivering high-quality medicines to patients in more than 165 countries and territories.
Viatris’ sustainable, diverse, and differentiated portfolio of medicines consists of more than 1,400 approved molecules across a wide range of key therapeutic areas, including world-renowned iconic and key brands, generics, complex generics, etc. The company operates manufacturing sites all over the world that produce oral solid doses, injectables, complex dosage forms, and active pharmaceutical ingredients. Around 40% of the more than 23 million people undergoing treatment for HIV use Viatris’ products, which includes 60% of the world’s HIV-positive children undergoing treatment.
The company is traded at the NASDAQ under the ticker symbol VTRS.
Did you like Viatris’ Revenue Breakdown by Region statistic?
Access more such KPI data points and segment financials on thousands of US stocks, with Business Quant.
You can get started here.
Always know what you’ll pay. No hidden costs or surprises.
* Billed annually, local taxes extra.
* Local taxes extra.